Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | ASCEND-ing results: acalabrutinib is well-tolerated and highly effective in R/R CLL

Paolo Ghia • 15 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib
ASCEND

Paolo Ghia, Università Vita-Salute San Raffaele, Milan, Italy, discusses the late-breaking abstract data on the ASCEND trial (NCT02970318) of acalabrutinib in previously treated chronic lymphocytic leukemia (CLL). This treatment was demonstrated to significantly prolong survival without disease progression, indicating that acalabrutinib has the potential to change current practice by providing a well-tolerated, highly effective BTK inhibitor treatment. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Paolo Ghia

1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals